{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T23:51:39Z","timestamp":1790725899572,"version":"4.1.0"},"reference-count":21,"publisher":"American Society for Microbiology","issue":"5","license":[{"start":{"date-parts":[[2025,5,7]],"date-time":"2025-05-07T00:00:00Z","timestamp":1746576000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2025,5,7]],"date-time":"2025-05-07T00:00:00Z","timestamp":1746576000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[2025,5,7]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n          <jats:sec>\n            <jats:title\/>\n            <jats:p>\n              Population pharmacokinetic analyses were undertaken to characterize epithelial lining fluid (ELF) penetration for tobramycin in pneumonia patients. A two-compartment model with zero-order intravenous input and first-order elimination linked to an effect site ELF compartment was utilized to determine the steady-state ELF penetration ratio of 0.51 for tobramycin. These results are useful to account for effect site exposure when performing analyses to support recommendations for aminoglycoside dosing regimens and interpretive criteria for\n              <jats:italic toggle=\"yes\">in vitro<\/jats:italic>\n              susceptibility testing.\n            <\/jats:p>\n          <\/jats:sec>","DOI":"10.1128\/aac.00908-24","type":"journal-article","created":{"date-parts":[[2025,4,14]],"date-time":"2025-04-14T13:01:36Z","timestamp":1744635696000},"update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":2,"title":["Population pharmacokinetic analysis of tobramycin in serum and ELF using data from patients with pneumonia"],"prefix":"10.1128","volume":"69","author":[{"given":"Scott A.","family":"Van Wart","sequence":"first","affiliation":[{"name":"Institute for Clinical Pharmacodynamics Inc","place":["Schenectady, USA"]},{"name":"Enhanced Pharmacodynamics, LLC","place":["Buffalo, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Trang","sequence":"additional","affiliation":[{"name":"Institute for Clinical Pharmacodynamics Inc","place":["Schenectady, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0452-682X","authenticated-orcid":true,"given":"M. Courtney","family":"Safir","sequence":"additional","affiliation":[{"name":"Institute for Clinical Pharmacodynamics Inc","place":["Schenectady, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew R.","family":"Santulli","sequence":"additional","affiliation":[{"name":"Enhanced Pharmacodynamics, LLC","place":["Buffalo, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3172-0847","authenticated-orcid":true,"given":"Christopher M.","family":"Rubino","sequence":"additional","affiliation":[{"name":"Institute for Clinical Pharmacodynamics Inc","place":["Schenectady, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4891-6467","authenticated-orcid":false,"given":"Sujata M.","family":"Bhavnani","sequence":"additional","affiliation":[{"name":"Institute for Clinical Pharmacodynamics Inc","place":["Schenectady, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.coph.2017.09.019"},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.2165\/11594090-000000000-00000"},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40262-021-01061-7"},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.1164\/arrd.1983.127.5.563"},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.1179\/joc.1995.7.4.363"},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00134-007-0688-x"},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.1177\/0885066618754784"},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.1378\/chest.128.2.545"},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.1378\/chest.101.4.1028"},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0009-9236(99)70103-7"},{"key":"e_1_3_2_12_2","unstructured":"Bauer RJ. 2017. NONMEM users guides. NONMEM 7. Version 7.4.1 ICON P.c. Gaithersburg MD"},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.1208\/s12248-011-9255-z"},{"key":"e_1_3_2_14_2","doi-asserted-by":"publisher","DOI":"10.1128\/aac.01393-23"},{"key":"e_1_3_2_15_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.1989.tb05431.x"},{"key":"e_1_3_2_16_2","doi-asserted-by":"publisher","DOI":"10.1023\/a:1008633526772"},{"key":"e_1_3_2_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/s0924-8579(00)00172-2"},{"key":"e_1_3_2_18_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.44.4.809-813.2000"},{"key":"e_1_3_2_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcf.2006.12.007"},{"key":"e_1_3_2_20_2","unstructured":"Tobramycin [package insert]. 2024. Lake Forest IL Hospira Inc"},{"key":"e_1_3_2_21_2","unstructured":"The United States Committee on Antimicrobial Susceptibility Testing (USCAST). 2019. Aminoglycoside in vitro susceptibility test interpretive criteria evaluations. http:\/\/www.uscast.org\/documents."},{"key":"e_1_3_2_22_2","volume-title":"USCAST 2023 Virtual Public Meeting. February 8, 2023","author":"The United States Committee on Antimicrobial Susceptibility Testing (USCAST)","year":"2023","unstructured":"The United States Committee on Antimicrobial Susceptibility Testing (USCAST). 2023. Re-evaluation of aminoglycoside in vitro susceptibility test interpretive criteria. USCAST 2023 Virtual Public Meeting. February 8, 2023. https:\/\/www.uscast.org\/presentations."}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/aac.00908-24","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/aac.00908-24","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,7]],"date-time":"2025-05-07T13:01:46Z","timestamp":1746622906000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/aac.00908-24"}},"subtitle":[],"editor":[{"given":"James E.","family":"Leggett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2025,5,7]]},"references-count":21,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,5,7]]}},"alternative-id":["10.1128\/aac.00908-24"],"URL":"https:\/\/doi.org\/10.1128\/aac.00908-24","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,7]]},"assertion":[{"value":"2024-06-19","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-11-21","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-04-14","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e00908-24"}}